Clinical Impact of EUS in Staging NSCLC

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The goal of this prospective study is to determine the clinical and economic impact of endoscopic ultrasound (EUS) in staging NSCLC. Aims: 1) Determine the accuracy of EUS in staging NSCLC 2) Measure 5-year survival 3) Measure quality of life in patients that undergo surgery 4) Determine the cost benefit of EUS in staging NSCLC.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02834936` - A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation	Phase 2
	Completed	`NCT00532155` - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer	Phase 3

NCT number	NCT00577746
Study type	Observational
Source	Indiana University
Contact
Status	Completed
Phase	N/A
Start date	June 2006
Completion date	September 2013

Clinical Impact of EUS in Staging NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms